This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Arsanis Biosciences GmbH
Drug Names(s): ASN 100, ASN-100
ASN-100 is a fully human MAb cocktail in development for the prevention and treatment of infections due to severe noscomial Staphylococcus aureus including, methicillin-resistant (MRSA) and methicillin sensitive (MSSA) strains.
ASN100 is a combination of two monoclonal antibodies (ASN-1 and ASN-2) designed to neutralize six cytolysins that are important in the pathogenesis of both MRSA and MSSA infections. ASN-1 neutralizes Hla and four of the five leukocidins, HlgAB, HlgCB, LukSF and LukED. ASN-2 inactivates the 5th leukocidin, LukGH.
These cytolysins are used by S. aureus to kill neutrophils, monocytes and macrophages. Blocking the detrimental effect of leukocidins on WBCs and neutralization of Hla may reduce the virulence, invasiveness and pathogenicity of S. aureus and enhance the ability of the human host to eliminate bacteria.
Additional information available to subscribers only: